Phase I Clinical Study on the Long-term Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1-expressing Refractory Solid tumor.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
Price : $35 *
At a glance
- Drugs IMF 001 (Primary) ; MIS 416 (Primary)
- Indications Prostate cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2012 New trial record